Bile Duct Cancer Market Trends, Manufacturers, Share, Opportunities, Strategies to Boost Growth, Applications
Bile Duct Cancer Market |
The bile duct is a tube network that connects the liver to the gallbladder. The bile duct transports bile, a fluid produced by the liver and stored in the gallbladder. Bile's primary function is to break down fats during digestion. Cholangiocarcinoma is the medical term for bile duct cancer. Long-term inflammation in the liver, biliary stones, abnormalities in the bile duct such as cysts, infection with the liver flukes parasite that causes infection in the bile duct leading to cancer, and exposure to harmful chemicals and toxins are all factors that contribute to the development of bile duct cancer. Jaundice, weight loss, loss of appetite, discoloration of urine and stool, abdominal pain, itching, and fever are all common symptoms of bile duct cancer.
The global bile duct cancer market is being driven by an
increase in the number of bile duct cancer patients worldwide, technological
advancement in the health care sector, and an increase in health care
expenditure in developed countries. Furthermore, new research and development
by pharmaceutical companies for the availability of affordable treatment via
extensive research is a major market driver.
The global bile duct cancer market has been segmented by treatment type,
cancer type, end-user, and region. The global market is divided into three
segments based on treatment type: surgery, chemotherapy, and radiation therapy.
Surgery treatments include bile duct removal,
partial keratectomy, and, in severe cases, the Whipple procedure and liver
transplantation. The market is divided into two types of cancer: intrahepatic
bile duct cancer and extrahepatic bile duct cancer. Intrahepatic bile duct
cancer is the formation of cancer within a bile duct within the liver. The
hilum region and the distal region comprise the extrahepatic bile duct.
Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems, Inc. are among the major players in the global bile duct cancer market.
Comments
Post a Comment